Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandpiper: Ad-MAGEA3 and MG1-MAGEA3 with pembrolizumab in NSCLC
NCT02879760Phase 2Completed
- Sponsor
- Turnstone Biologics
- Start
- Mar 2017
- Primary completion
- Feb 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of mg1-magea3, Ad-MAGEA3 in non-small cell lung cancer (NSCLC), sponsored by Turnstone Biologics. Started Mar 2017; status: completed.
02
Drugs
mg1-magea3Ad-MAGEA3
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02879760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879760.